Annotation of rs1476413

Genotypes CC + CT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.

Those with the CC and CT genotype were more likely to be a responder to treatment. The association was not significant after multiple comparison correction.

From Publication

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics. 2014. Salazar Juliana et al.
PMID:25084201(opens in new window) DOI:10.2217/pgs.14.67(opens in new window)

Gene

MTHFR

Variant

rs1476413

Phenotype Category

Efficacy

Association Significance

The study reports this association is not significant

PharmGKB ID

1184748734

Score
More info on scoring

0

Evidence for Clinical Annotations

This annotation has been used as evidence for the following clinical annotations.

  1. Clinical Annotation for rs1476413 (MTHFR); methotrexate; Arthritis, Rheumatoid (level 3 Efficacy)

Study Parameters

Study type

cohort

Study size

61 (cases=45; controls=16)

Association p-value

= 0.0086

Statistical analysis

OR: 3.56

Confidence interval

1.28 - 9.91

Allele frequency

C: case=0.79, control=0.56

Population description

Study Cohort: Here cases = responders to methotrexate treatment, controls = nonresponders (DAS28 score at end point higher than 5.1 and improvement was 0.6 or less over the baseline DAS28). Patients were treated with methotrexate for at least 6 months.

Note: Alleles in PharmGKB are mapped to the positive chromosomal strand. Therefore, variants in genes on the "minus" strand (eg. VKORC1) are complemented in PharmGKB annotations.

History

No history available.